|
February 8, 2010
|
| 09:47 EDT |  | PFE |
| theflyonthewall.com: | Active equity option families in first 10-minutes of trading | | Active equity option families in first 10-minutes of trading according to Track Data are: PFE BAC CVS AMZN. :theflyonthewall.com |
|
| 07:29 EDT |  | PFE |
|
| 07:18 EDT |  | PFE |
| theflyonthewall.com: | Pfizer to deploy e-payment system in developing markets, FT says | | Pfizer (PFE) is launching an e-payment system in Russia this month that will allow many users of the company's drugs there to receive substantial discounts on their medicine. The system - which Pfizer also plans to deploy to Mexico, Brazil and Venezuela -may boost the use of high-price drugs while facilitating the company's marketing efforts, according to the newspaper. Reference Link :theflyonthewall.com |
|
| 07:03 EDT | | PFE |
| theflyonthewall.com: | On The Fly: Periodicals Wrap-Up | | WALL STREET JOURNAL: Amazon (AMZN) and Macmillan have settled their pricing dispute, reports the Wall Street Journal...IBM Corp. (IBM) is introducing its next generation of microprocessor chips and systems that use them, hoping to extend the computer giant's recent lead in the market for mid-range servers, reports the Wall Street Journal...BLOOMBERG: Treasury Secretary Geithner said the U.S. is not in danger of losing its Aaa debt rating even though the Obama administration has predicted a $1.6T budget deficit in 2010, Bloomberg reports...GLOBES: Pfizer (PFE) is set to sell Viagra, its drug for treating impotence, legally in Israel on the Internet, reports Globes. :theflyonthewall.com |
|
| 06:14 EDT | | PFE |
|
|
February 5, 2010
|
| 11:57 EDT |  | PFE |
|
| 07:41 EDT | | PFE |
|
| 06:44 EDT | | PFE |
|
|
February 4, 2010
|
| 16:02 EDT | | PFE |
| theflyonthewall.com: | Pfizer enters agreement with Qiagen | | Pfizer (PFE) and DxS, a wholly owned subsidiary of Qiagen (QGEN) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme. Financial terms of the diagnostic agreement have not been disclosed. :theflyonthewall.com |
|
| 11:40 EDT | | PFE |
|
| 10:11 EDT | | PFE |
|
| 09:44 EDT | | PFE |
|
| 07:11 EDT | | PFE |
| theflyonthewall.com: | Pfizer to reduce R&D as it absorbs Wyeth, WSJ reports | | Pfizer (PFE) plans to cut its R&D spending by up to $3B by 2012, which was more than 25% of the combined R&D of Pfizer and newly acquired Wyeth in 2008, reports the Wall Street Journal. The move is based on efficiencies without hurting future product development. Reference Link :theflyonthewall.com |
|
|
February 3, 2010
|
| 14:17 EDT | | PFE |
| theflyonthewall.com: | Pfizer sinks after reporting Q4 earnings and guidance | | Pfizer (PFE) reported Q4 EPS 49c vs. consensus of 50c, and gave FY10 EPS guidance $2.10-$2.20 vs. a consensus $2.27. Pfizer's Q4 results were helped by accretion from the Wyeth acquisition, cost cutting and strong sales from Lyrica and Sutent. On its Q4 conference call, the CFO said, "2010 revenue and EPS guidance was negatively impacted by the recent unfavorable changes in foreign exchange. For example, based on exchange rates in late January, the strengthening of the U.S. dollar has decreased our adjusted diluted EPS guidance by about 6c." Also weighing on Pfizer's shares was a cut in 2012 profit and revenue forecasts, which coincides with the loss of the U.S. patent for Lipitor in November 2011. In early afternoon trading, shares of Pfizer were down 52c, or 2.8%, to 18.54. :theflyonthewall.com |
|
| 12:14 EDT |  | PFE |
|
| 09:56 EDT |  | PFE |
|
| 09:53 EDT | | PFE |
|
| 07:30 EDT |  | PFE |
| theflyonthewall.com: | Pfizer sees FY12 EPS $2.25-$2.35 | | Sees FY12 revenue $66B-$68.5B. Consensus estimates are unavailable. :theflyonthewall.com |
|
| 07:29 EDT | | PFE |
|
| 07:11 EDT | | PFE |
|
| 07:10 EDT | | PFE |
| theflyonthewall.com: | Pfizer freports Q4 EPS 49c vs. consensus of 50c | | Reports Q4 revenue $16.53B vs. consensus $15.88B. :theflyonthewall.com |
|
| 07:02 EDT | | PFE |
| theflyonthewall.com: | On The Fly: Periodicals Wrap-Up | | WALL STREET JOURNAL: China on Tuesday renewed its pledge to punish U.S. companies that are involved in Washington's plan to sell weapons to Taiwan, in another sign of Beijing's increasingly assertive foreign policy, reports the Wall Street Journal...Home builders have lost half their share of the U.S. housing market in the past two years, largely because of competition from cheap foreclosed houses, reports the Wall Street Journal. In 2009 only 7.6% of the homes sold were newly constructed, down from the average of about 16% over the previous two decades. But home builders are fighting back, cutting prices, promising to complete homes faster, and warning about the risks of buying foreclosed property...DETROIT NEWS: As it deals with massive global recalls, Toyota (TM) has reportedly also received over 100 complaints in Japan and the U.S. about brake problems with the Prius hybrid, the Detroit News reports...GLOBES: Pfizer (PFE) has reportedly dropped out of the running for Ratiopharm, and now Teva (TEVA) may be close to an acquisition of the German pharmaceuticals company, reports Globes. Teva is still up against Actavis, which is backed by private equity firm EQT, for Ratiopharm. The acquisition price is likely to be about $4.17B...BARRON'S: Analysts still don't think Under Armour (UA) is a bargain, Barrons.com reports. An unprecedented misstep on Under Armour's latest footwear roll-out damaged the company's reputation for new-product launches, and hurt its financial performance. :theflyonthewall.com |
|
| 06:04 EDT | | PFE |
| theflyonthewall.com: | Teva may be close to acquisition for Ratiopharm, Globes reports | | Pfizer (PFE) has reportedly dropped out of the running for Ratiopharm, and now Teva (TEVA) may be close to an acquisition of the German pharmaceuticals company. Teva is still up against Actavis, which is backed by private equity firm EQT, for Ratiopharm. The acquisition price is likely to be about $4.17B. Reference Link :theflyonthewall.com |
|
|
February 2, 2010
|
| 16:02 EDT | | PFE |
|
| 13:07 EDT |  | PFE |
| theflyonthewall.com: | Pfizer: Earnings release technical preview, high gap risk, very small short-base | | BULLISH CASE: On better than expected news/outlook the stock could trade to the upper limit of the bullish price channel at $19.20. On a bullish breakout above the price channel the following resistance levels would become upside objectives: $19.69, $20.13, $20.65, $21.10, $21.56, $21.98, $22.51, $22.92, $23.36. BEARISH CASE: On worse than expected news/outlook the stock could trade to the lower limit of the price channel at $18.65 -- also the 50-day moving average, and longer-term uptrend support line proxy. On a bearish breakdown below the price channel the following support levels would become downside objectives: $18.27, $17.92, $17.65, $17.34, $17.02, $16.72, $16.46, $16.19, $15.95, $15.68. NOTE: Very small short-base at 1 day to cover, with 0.6% of the float short. Traders are positioned for positive news. Reactions on a surprise, especially a negative one given the very small short-base, have a high probability of being extreme in duration and price. High gap risk. :theflyonthewall.com |
|
| 07:00 EDT | | PFE |
| theflyonthewall.com: | Pfizer partner may release data on Alzheimer's treatment soon, Bloomberg says | | Medivation (MDVN), which is working with Pfizer (PFE) to turn a hay fever treatment called Dimebon into an Alzheimer's remedy, may announce data on its innovation at the beginning of next month, according to Bloomberg, which cited a leader of the European trials for the product. Dimebon may become the world's top Alzheimer's treatment, according to Bloomberg. Reference Link :theflyonthewall.com |
|
|
February 1, 2010
|
| 08:47 EDT | | PFE |
|
| 06:35 EDT | | PFE |
| theflyonthewall.com: | Pfizer may form alliance in Japan to compete with generics, Reuters reports | | Pfizer (PFE) aims to capitalize on its brand name and business expertise in Japan to compete with rivals such as Israel's Teva Pharmaceutical (TEVA), Reuters reports. Unlike Teva, which is using a joint venture with Japanese drugmaker Kowa to enter the market, Pfizer prefers to form an alliance without a joint venture, Hiroshi Matsumori, corporate officer at Pfizer Japan said. Pfizer's goal is is to grab less than 10% market share in Japan by 2020. Reference Link :theflyonthewall.com |
|
|
January 31, 2010
|
| 22:09 EDT | | PFE |
| theflyonthewall.com: | Barron's says, brokerage firms appear are regaining their stock-picking prowess |
 Subscribe for More Information :theflyonthewall.com |
|
|
January 29, 2010
|
| 11:18 EDT | | PFE |
|
| 07:56 EDT | | PFE |
|
|
January 27, 2010
|
| 12:05 EDT | | PFE |
|
| 12:04 EDT | | PFE |
| theflyonthewall.com: | Pfizer provides pipeline update | | Pfizer provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline includes 133 programs from phase 1 through registration. Pfizer has identified six "Invest to Win" areas of research where there exist significant opportunities for innovation and market leadership: oncology; pain; inflammation; Alzheimer’s disease; psychoses; and diabetes. :theflyonthewall.com |
|
